Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Shunta Mori"'
Autor:
Shunta Mori, Hiroki Izumi, Mitsugu Araki, Jie Liu, Yu Tanaka, Yosuke Kagawa, Yukari Sagae, Biao Ma, Yuta Isaka, Yoko Sasakura, Shogo Kumagai, Yuta Sakae, Kosuke Tanaka, Yuji Shibata, Hibiki Udagawa, Shingo Matsumoto, Kiyotaka Yoh, Yasushi Okuno, Koichi Goto, Susumu S. Kobayashi
Publikováno v:
Communications Biology, Vol 7, Iss 1, Pp 1-10 (2024)
Abstract The CLIP1-LTK fusion was recently discovered as a novel oncogenic driver in non-small cell lung cancer (NSCLC). Lorlatinib, a third-generation ALK inhibitor, exhibited a dramatic clinical response in a NSCLC patient harboring CLIP1-LTK fusio
Externí odkaz:
https://doaj.org/article/d5116c53bf5a493298d2e20157408e3f
Autor:
Yosuke Kagawa, MD, Takuma Hayashida, MS, Jie Liu, BS, Shunta Mori, MD, Hiroki Izumi, MD, PhD, Shogo Kumagai, MD, PhD, Hibiki Udagawa, MD, PhD, Noboru Hattori, MD, PhD, Koichi Goto, MD, PhD, Susumu S. Kobayashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 3, Pp 100462- (2023)
Introduction: EGFR exon 20 insertion mutations account for 5% to 10% of EGFR-mutated NSCLC. CLN-081 (formerly known as TAS6417), a novel covalent EGFR tyrosine kinase inhibitor, exhibits pan-mutation selective efficacy, including exon 20 insertions,
Externí odkaz:
https://doaj.org/article/e3d98b0bb20a49d68b4a9a9c19b6c29e
Autor:
Wataru Katano, Shunta Mori, Shun Sasaki, Yuki Tajika, Koichi Tomita, Jun K. Takeuchi, Kazuko Koshiba-Takeuchi
Publikováno v:
Development (09501991); 12/15/2023, Vol. 150 Issue 24, p1-15, 15p
Autor:
Kaname Nosaki, Jun Sakakibara-Konishi, Ichiro Nakachi, Yoshitaka Zenke, Kageaki Taima, Keisuke Kirita, Kiyotaka Yoh, Shunta Mori, Genichiro Ishii, Shoichi Kuyama, Tatsuro Fukuhara, Shingo Matsumoto, Shogo Kumagai, Hiroki Izumi, Yuji Shibata, Seiji Niho, Noriyuki Ebi, Takaya Ikeda, Jie Liu, Tokiko Nakai, Masahiro Kodani, Haruko Daga, Terufumi Kato, Tetsuya Sakai, Koichi Goto, Atsushi Ohtsu, Kosuke Tanaka, Eri Sugiyama, Atsushi Nakamura, Kana Watanabe, Takuma Hayashida, Isamu Okamoto, Susumu Kobayashi, Kazumi Nishino, Kumiko Hayashi, Naoki Furuya, Hibiki Udagawa, Akira Yamasaki
Publikováno v:
Nature. 600:319-323
Lung cancer is one of the most aggressive tumour types. Targeted therapies stratified by oncogenic drivers have substantially improved therapeutic outcomes in patients with non-small-cell lung cancer (NSCLC)1. However, such oncogenic drivers are not
Autor:
Gaku Yamamoto, Kosuke Tanaka, Ryo Kamata, Shunta Mori, Jie Liu, Toyohiro Yamauchi, Yuta Sakae, Akihiro Ohashi, Susumu S. Kobayashi
Publikováno v:
Cancer Research. 83:5739-5739
Background: While sotorasib is the first clinically approved small-molecule inhibitor of KRAS G12C in non-small-cell lung cancer (NSCLC), efficacy of sotorasib alone is limited, presumably due to adaptive resistance mechanisms in cancer cells. To exp
Autor:
Naoyuki Nogami, Shunta Mori, Yumi Asakura, Daijiro Harada, Kenji Takata, Takayuki Ohno, Satoko Moriki, Toshiyuki Kozuki, Yoshika Takechi
Publikováno v:
Anticancer Research. 39:4987-4993
Background/aim For immune checkpoint inhibitor (ICI)-pretreated patients, docetaxel and ramucirumab (DOC+RAM) combination therapy may be more effective compared to patients not receiving ICI treatment. Patients and methods From June 2013 to July 2018
Autor:
Hiroki, Izumi, Shingo, Matsumoto, Jie, Liu, Kosuke, Tanaka, Shunta, Mori, Kumiko, Hayashi, Shogo, Kumagai, Yuji, Shibata, Takuma, Hayashida, Kana, Watanabe, Tatsuro, Fukuhara, Takaya, Ikeda, Kiyotaka, Yoh, Terufumi, Kato, Kazumi, Nishino, Atsushi, Nakamura, Ichiro, Nakachi, Shoichi, Kuyama, Naoki, Furuya, Jun, Sakakibara-Konishi, Isamu, Okamoto, Kageaki, Taima, Noriyuki, Ebi, Haruko, Daga, Akira, Yamasaki, Masahiro, Kodani, Hibiki, Udagawa, Keisuke, Kirita, Yoshitaka, Zenke, Kaname, Nosaki, Eri, Sugiyama, Tetsuya, Sakai, Tokiko, Nakai, Genichiro, Ishii, Seiji, Niho, Atsushi, Ohtsu, Susumu S, Kobayashi, Koichi, Goto
Publikováno v:
Cancer Cell
Identification of targetable fusions as oncogenic drivers in non-small cell lung cancer has transformed its diagnostic and therapeutic paradigm. In a recent article in Nature, Izumi et al. report the discovery of CLIP1-LTK fusion as a novel oncogenic
Autor:
Hiroki Izumi, Shingo Matsumoto, Shunta Mori, Kumiko Hayashi, Kana Watanabe, Tatsuro Fukuhara, Yuji Shibata, Kiyotaka Yoh, Masahiro Morise, Ryo Toyozawa, Kenichi Chikamori, Shingo Miyamoto, Shuichi Asano, Masato Shingyoji, Mika Nakao, Koichi Azuma, Seiji Niho, Genichiro Ishii, S. Susumu Kobayashi, Koichi Goto
Publikováno v:
Annals of Oncology. 33:S464
Autor:
Takuma Hayashida, Yosuke Kagawa, Shunta Mori, Liu jie, Yukie Kashima, Kosuke Tanaka, Hibiki Udagawa, Hiroki Izumi, Susumu Kobayashi
Publikováno v:
Cancer Research. 82:5355-5355
Background: EGFR exon 20 insertions are detected in approximately 10% of EGFR mutant non-small cell lung cancer (NSCLC). NSCLC with EGFR exon 20 insertions is resistance to conventional epidermal growth factor receptor tyrosine kinase inhibitors (EGF
Autor:
Hiroki Izumi, Shingo Matsumoto, Jie Liu, Kosuke Tanaka, Shunta Mori, Shogo Kumagai, Takuma Hayashida, Yuji Shibata, Saori Takata, Eriko Tabata, Haruyasu Murakami, Reiko Taki, Satoshi Hara, Tomohiro Sakamoto, Koichi Goto, Susumu S. Kobayashi
Publikováno v:
Cancer Research. 82:5238-5238
Background: The discovery of oncogenic driver has uncovered the pathogenesis of non-small cell lung cancer (NSCLC), and development of corresponding kinase inhibitors has changed treatment strategies and improved survival of patients with druggable o